Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph G Zinner

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|March 12, 2009
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cellsRalph G Zinner, Brittany L Barrett, Elmira Popova, et al.
Cancer|July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsGoldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Cancer|November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing diseaseRalph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|March 12, 2009
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cellsRalph G Zinner, Brittany L Barrett, Elmira Popova, et al.
Cancer|July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsGoldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Cancer|November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing diseaseRalph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Pageof 5